Is Zepbound Safe? Risks and Considerations

Is Zepbound safe? For most adults who qualify, Zepbound (tirzepatide) is an FDA-approved prescription medicine with a defined safety profile, but “safe” is never absolute. It carries a boxed warning derived from animal studies, several contraindications, and a list of warnings and precautions, and the most common side effects are gastrointestinal. Whether it is appropriate for you depends on your medical history and is a decision for a licensed provider. This article summarizes what the FDA label and the pivotal clinical trials actually report so you can have an informed conversation.

What is Zepbound, and what is it approved for?

Zepbound is the brand name for tirzepatide, a once-weekly injectable that activates two gut hormone receptors, GIP and GLP-1. The FDA approved Zepbound on November 8, 2023 for chronic weight management in adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related condition, used alongside a reduced-calorie diet and increased physical activity. On December 20, 2024, the FDA also approved it as the first prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity.

Tirzepatide is the same molecule as Mounjaro; Zepbound is the brand for obesity and sleep apnea, while Mounjaro is approved for type 2 diabetes. Wegovy and Ozempic are a different drug, semaglutide. If you are weighing these against each other, see our overviews of Zepbound vs. Mounjaro and tirzepatide vs. semaglutide.

What does the Zepbound boxed warning mean?

Zepbound carries a boxed warning, the FDA’s most prominent caution. According to the FDA prescribing information, tirzepatide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors in rats at clinically relevant exposures. The label is explicit that it is unknown whether Zepbound causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, because the human relevance of the rodent findings has not been determined.

In plain terms: this is an animal-study signal, not a confirmed human cancer risk. Because the question is unresolved, the label pairs the warning with a firm contraindication, described next, and advises patients to report symptoms such as a neck mass, trouble swallowing, shortness of breath, or persistent hoarseness to their provider.

Who should not take Zepbound?

The FDA label lists clear contraindications. Per the prescribing information, Zepbound is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC), in people with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and in anyone with a known serious hypersensitivity to tirzepatide or its ingredients.

Beyond outright contraindications, the label flags groups who need extra caution and a careful provider discussion: people with a history of pancreatitis, pre-existing gallbladder or biliary disease, severe gastrointestinal disease or severe gastroparesis (where it is not recommended), diabetic retinopathy, and those with type 2 diabetes taking insulin or a sulfonylurea. Pregnancy is also a consideration, and the label includes an oral-contraceptive efficacy note worth raising with your clinician. These are reasons to discuss your history with a licensed provider, not a checklist for self-diagnosis.

What are the most common Zepbound side effects?

The most common adverse reactions are gastrointestinal and are mostly mild to moderate, occurring predominantly during dose escalation and decreasing over time. The table below reports the incidence from the FDA label’s pooled adverse-reaction table from Studies 1 and 2 (SURMOUNT-1 in adults with obesity or overweight without type 2 diabetes, and SURMOUNT-2 in adults with obesity or overweight and type 2 diabetes), shown by the 5-mg, 10-mg, and 15-mg doses versus placebo.

Adverse reaction	5 mg	10 mg	15 mg	Placebo
Nausea	25%	29%	28%	8%
Diarrhea	19%	21%	23%	8%
Constipation	17%	14%	11%	5%
Vomiting	8%	11%	13%	2%
Abdominal pain	9%	9%	10%	5%
Dyspepsia	9%	9%	10%	4%
Injection-site reactions	6%	8%	8%	2%

Source: FDA Zepbound prescribing information, Adverse Reactions Table 1 — pooled Studies 1 and 2 (SURMOUNT-1 without type 2 diabetes, SURMOUNT-2 with type 2 diabetes).

These figures reflect the pooled Study 1 and Study 2 populations (with and without type 2 diabetes) and should not be generalized to other tirzepatide products or to semaglutide. For a fuller breakdown, see our guide to tirzepatide side effects and how dosing is titrated in the tirzepatide dosage chart. Gradual dose escalation is the standard approach used to reduce these GI effects.

What serious risks does the label warn about?

The FDA label’s warnings and precautions describe several less common but more serious risks, summarized below.

Risk	What the label reports
Acute pancreatitis	Fatal and non-fatal hemorrhagic or necrotizing pancreatitis has been observed with GLP-1 receptor agonists; the label advises discontinuing if pancreatitis is suspected. Causality with tirzepatide is not established.
Acute gallbladder disease	In trials, cholelithiasis (gallstones) occurred in 1.1% of Zepbound-treated patients vs. 1% on placebo, and cholecystitis in 0.7% vs. 0.2%.
Hypoglycemia	In type 2 diabetes patients, combining Zepbound with insulin or a sulfonylurea may raise low-blood-sugar risk. In Study 2, hypoglycemia occurred in 10.3% of those also taking a sulfonylurea vs. 2.1% of those not — this figure applies only to that diabetes subgroup.
Acute kidney injury	Postmarketing reports, mostly in patients with GI reactions (nausea, vomiting, diarrhea) leading to dehydration. Not recommended in severe gastroparesis.
Other precautions	The label also addresses diabetic retinopathy, pulmonary aspiration during anesthesia or deep sedation, and serious hypersensitivity reactions.

Source: FDA Zepbound prescribing information, Warnings and Precautions.

Report severe or persistent abdominal pain, signs of an allergic reaction, or symptoms of dehydration to your provider promptly. If you have an elective surgery or procedure requiring general anesthesia or deep sedation planned, tell your healthcare provider that you take tirzepatide. These precautions are why tirzepatide is prescription-only and dispensed under clinical oversight rather than self-managed.

How well were Zepbound’s safety data studied?

The obesity safety dataset is substantial. SURMOUNT-1, published in the New England Journal of Medicine, was a 72-week phase 3 trial of 2,539 adults with obesity or overweight without type 2 diabetes. The most common adverse events were gastrointestinal and mostly mild to moderate, occurring primarily during dose escalation. Adverse events led to treatment discontinuation in 4.3%, 7.1%, and 6.2% of the 5-mg, 10-mg, and 15-mg tirzepatide groups, respectively, versus 2.6% with placebo.

A large, multi-year trial program does not eliminate risk, but it gives clinicians a well-characterized profile to weigh against an individual’s goals and history. Any weight-loss or sleep-apnea outcomes from these trials are study-specific averages; individual results vary and are determined with your provider. If you are exploring a broader picture, our overview of peptides for weight loss adds context.

Is compounded tirzepatide the same as Zepbound?

No. Compounded tirzepatide is not the FDA-approved branded product. According to the FDA, compounded GLP-1 products are not FDA-approved, have not been evaluated by the FDA for safety, effectiveness, or quality, and have been linked to dosing errors and adverse-event reports; they may also contain different ingredients, salt forms, or impurities than the approved drug.

The regulatory landscape changed in 2024 and 2025. The FDA removed tirzepatide from the drug shortage list in October 2024 and declared the semaglutide shortage resolved in February 2025; with national GLP-1 supply stabilizing, the agency has since clarified its policies for compounders. Compounding enforcement-discretion grace periods ended by May 2025, after which mass compounding of these drugs is no longer permitted. As a result, any compounded tirzepatide today is an individualized, provider-determined prescription, not shortage-driven mass production. The branded label’s safety data describe Zepbound specifically and should not be assumed to apply identically to a compounded preparation.

Frequently asked questions

Does Zepbound cause thyroid cancer?

It is unknown. The boxed warning is based on thyroid C-cell tumors seen in rats; the FDA label states the human relevance has not been determined, so it should not be read as a proven human cancer risk. People with a personal or family history of medullary thyroid carcinoma or MEN 2 should not take it. Discuss your history with a licensed provider.

What are the most common Zepbound side effects?

In the FDA label’s pooled Studies 1 and 2 (SURMOUNT-1 without type 2 diabetes and SURMOUNT-2 with type 2 diabetes), the most common reactions were gastrointestinal: nausea (25-29% across doses vs. 8% placebo), diarrhea, constipation, vomiting, abdominal pain, and dyspepsia, plus injection-site reactions. Most were mild to moderate and concentrated during dose escalation.

Who should not take Zepbound?

Per the FDA label, Zepbound is contraindicated in people with a personal or family history of medullary thyroid carcinoma, those with MEN 2, and anyone with a known serious hypersensitivity to tirzepatide or its ingredients. Extra caution applies to people with prior pancreatitis, gallbladder disease, severe gastroparesis, diabetic retinopathy, or diabetes treated with insulin or a sulfonylurea.

Can Zepbound cause low blood sugar?

On its own the risk is low, but the label notes that in people with type 2 diabetes, combining it with insulin or a sulfonylurea raises hypoglycemia risk. In Study 2, hypoglycemia occurred in 10.3% of those also on a sulfonylurea versus 2.1% of those not. This figure applies specifically to that diabetes subgroup.

Is compounded tirzepatide FDA-approved?

No. Compounded tirzepatide is not FDA-approved and has not been evaluated by the FDA for safety, quality, or effectiveness. It is prescription-only and individualized. The FDA-approved branded product is Zepbound (and Mounjaro for diabetes). Eligibility for any version should be determined with a licensed provider.

Is Zepbound the same as Mounjaro or Ozempic?

Zepbound and Mounjaro are both tirzepatide — Zepbound is approved for obesity and obstructive sleep apnea, Mounjaro for type 2 diabetes. Ozempic and Wegovy are semaglutide, a different molecule, so their side-effect data should not be applied to tirzepatide.